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Recent studies have suggested that the kisspeptin (KP) and kissorphin (KSO) peptides have neuroprotective actions against the
Alzheimer’s amyloid-𝛽 (A𝛽) peptide. Overexpression of the human KiSS-1 gene that codes for KP and KSO peptides in SH-
SY5Y neurons has also been shown to inhibit A𝛽 neurotoxicity. The in vivo actions of KP include activation of neuroendocrine
and neurotransmitter systems. The present study used antagonists of KP, neuropeptide FF (NPFF), opioids, oxytocin, estrogen,
adrenergic, cholinergic, dopaminergic, serotonergic, and 𝛾-aminobutyric acid (GABA) receptors plus inhibitors of catalase,
cyclooxygenase, nitric oxide synthase, and the mitogen activated protein kinase cascade to characterize the KiSS-1 gene overex-
pression neuroprotection against A𝛽 cell model. The results showed that KiSS-1 overexpression is neuroprotective against A𝛽 and
the action appears to involve the KP or KSO peptide products of KiSS-1 processing. The mechanism of neuroprotection does not
involve the activation of the KP or NPFF receptors. Opioids play a role in the toxicity of A𝛽 in the KiSS-1 overexpression system
and opioid antagonists naloxone or naltrexone inhibited A𝛽 toxicity. The mechanism of KiSS-1 overexpression induced protection
against A𝛽 appears to have an oxytocin plus a cyclooxygenase dependent component, with the oxytocin antagonist atosiban and
the cyclooxygenase inhibitor SC-560 both enhancing the toxicity of A𝛽.
1. Introduction
Recent studies have suggested that the kisspeptin (KP) and
kissorphin (KSO) peptide derivatives of the metastasis-sup-
pressor KiSS-1 genemay have neuroprotective actions against
the Alzheimer’s amyloid-𝛽 (A𝛽) peptide [1]. The studies have
also suggested that stable overexpression of the KiSS-1 gene
in SH-SY5Y neurons creates a cell line that is resistant to the
neurotoxicity of A𝛽 [1]. The primary role of KP peptides is
as a regulator of hypothalamic-pituitary-gonadal- (HPG-)
axis via stimulation of gonadotrophin-releasing hormone
(GnRH) release [2].The KP peptides are ligands for the GPR-
54 receptor [3–7] and the neuropeptide FF (NPFF) receptors,
NPFFR1 (GPR-147) and NPFFR2 (GPR-74) [3, 4, 6–9]. The
KSO peptides have been suggested to be ligands for the NPFF
receptors but not theGPR-54 receptor [10]. BothKP andKSO
peptides are protective against the A𝛽 peptide in vitro [1].
However, the neuroprotective actions of KP and KSO pep-
tides have been suggested not to be mediated via actions on
GPR-54 or NPFF receptors [1]. Fibrillar A𝛽 peptides stimu-
late the release of KP peptides [1, 11] and KP has been suggest-
ed to colocalizewithA𝛽 deposits in theAlzheimer’s brain [11].
The actions of KP peptides are thought to bemediated via
activation of either GPR-54 or NPFF receptors. However, in
vivo actions on the opioid system [12, 13], oxytocin/vaso-
pressin systems [4, 14, 15], neurotransmitter systems [16, 17],
activation of endogenous antioxidants [18], activation of
nitric oxide [17], and possible activation of prostaglandin syn-
thesis [19] have not been tested with GPR-54 or NPFF
receptor antagonists.
The present study was conducted to characterize a model
of KiSS-1 gene overexpression neuroprotection against A𝛽 in
SH-SY5Y neurons in vitro [1] and to determine the role of
neurotransmitter systems in the neuroprotection. The effects
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of antagonists of KP, NPFF, opioids, oxytocin, estrogen,
adrenergic, cholinergic, dopaminergic, serotonergic, and 𝛾-
aminobutyric acid (GABA) receptors were tested. Inhibitors
of catalase, cyclooxygenase, nitric oxide synthase, and the
mitogen activated protein kinase cascade were also tested.
2. Materials and Methods
2.1. Materials. Synthetic A𝛽 peptides plus anti-kisspeptin
antibody were obtained from Bachem. Human SH-SY5Y
neuroblastoma cell line was obtained from the Health
Protection Agency Cell Culture Collection. ASCAT peptide
was obtained from Insight Biotechnology Ltd. 3-Amino-
1,2,4-triazole, atosiban, atropine sulphate, 1(S),9(R)-(−)-
bicuculline methiodide, BTA-EG4 hydrate, cyproheptadine
hydrochloride, DAPT, haloperidol, KP234, mecamylamine
hydrochloride, methysergide maleate, naltrexone, NG-
Methyl-L-arginine acetate salt, PD98059, phenoxybenzamine
hydrochloride, prazosin hydrochloride, propranolol hydro-
chloride, RF9, SC-560, tamoxifen, and yohimbine hydro-
chloride, plus all other chemicals, were obtained from
Sigma-Aldrich.
2.2. A𝛽 Fibril Formation. Batches of synthetic A𝛽 1–40 or
A𝛽 25–35 were dissolved in distilled water at a concentration
of 1.0mg/mL and incubated at 37∘C for 24 h, with constant
oscillation. Following incubation, the formation of fibrils was
confirmed by TEM or Congo red assay as previously de-
scribed by Milton and Harris [20–22].
2.3. Cell Cultures and KiSS-1 Overexpression. Human SH-
SY5Y neuroblastoma cells were routinely grown in a 5% CO
2
humidified incubator at 37∘C in a 1 : 1 mixture of Dulbecco’s
modified Eagle’s medium and HAM’s F12 with Glutamax
(Invitrogen) supplemented with 10% fetal calf serum (FCS),
1% nonessential amino acids, penicillin (100 units/mL), and
streptomycin (100mg/mL) [23]. The human KiSS-1 cDNA
clone (NM 002256) was obtained from Origene and PCR
cloned into the pcDNA4/TO/myc-His expression vector
using forward (5󸀠-TTAGGATCCATGAACTCACTGGTT-
TCTTGGCA-3󸀠) and reverse (5󸀠-ATACTCGAGGCCCCG-
CCCAGCGCTTCT-3󸀠) oligonucleotides to create the PKiSS
expression vector. SH-SY5Y cells were transfectedwith PKiSS
or control vector using lipofectamine (Invitrogen), and stably
expressing clones were selected by culturing in 100𝜇g/mL
Zeocin (Invitrogen). The presence of KiSS-1 overexpression
was confirmed by immunocytochemistry and RT-PCR anal-
ysis. Human neuroblastoma SH-SY5Y, PKiSS, and PVect
cells were cultured in 96-well plates and differentiated with
retinoic acid for 7 days prior to experimentation.
2.4. Immunocytochemistry. Cells were washed with PBS,
fixed with 4% paraformaldehyde for 15min, and permeabi-
lized in ice cold methanol for 30min. Cells were incubated in
block solution (10%bovine serumalbumin inPBS) for 15min,
followed by incubation with primary antibody anti-KP 45–
54 (1 : 1000) in block solution for 1 h. Primary antibody was
removed followed by 3 × 5min washes in PBS, prior to
incubation with goat anti-rabbit IgG-Alexa-fluor 488 sec-
ondary (Abcam PLC, Cambridge; 1 : 500) in block solution
for 45min. Secondary antibody was removed and cells were
washed 3 times in PBS. Cells were incubated with 100𝜇g/mL
RNase A for 20min at 37∘C, followed by 3 × 5min washes
and incubation with 1 𝜇MTO-PRO-3 Iodide (642/661; Invit-
rogen) for 20min. Cells were washed 3 times in PBS and fluo-
rescence was visualized by sequential scanning using a Leica
TCS SP2 confocal system (Leica Microsystems, Milton
Keynes, UK) [11].
2.5. Western Blotting of Conditioned Media. To determine
the presence of KP released into the media from KiSS-1-
overexpressing and vector control cells proteins were purified
from 6mls of conditioned media using an Amicon system
(MerckMillipore UK). Proteins in extracts were resuspended
in sample buffer before boiling for 5min and separation of
samples using a 15% SDS-PAGE gel. Proteins were then trans-
ferred to a nitrocellulose membrane and membranes were
blocked with 3% nonfat driedmilk powder in PBS containing
0.1% Tween 20 (1 h at room temperature). Membranes were
incubated overnight at 4∘C with rabbit anti-KP 45−54 anti-
body. Unbound antibody was rinsed from the membranes
before incubation with horseradish peroxidase-conjugated
goat anti-rabbit secondary antibody. Immunoreactivity was
detected using an enhanced chemiluminescence substrate
and UVP BioImaging system.
2.6. Reverse Transcription Polymerase Chain Reaction (RT-
PCR). To determine the steady-state levels of KiSS-1 mRNA,
total RNA was isolated from KiSS-1-overexpressing and vec-
tor control cells using a Qiagen RNeasy extraction kit (Cat
No: 74104) according to the manufacturer’s instructions. RT-
PCR was performed using the Qiagen one-step RT-PCR rea-
gent kit (Cat. no: 210210) with KiSS-1 forward 5󸀠-
TTAGGATCCATGAACTCACTGGTTTCTTGGCA-3󸀠 and
reverse (5󸀠-ATACTCGAGGCCCCGCCCAGCGCTTCT-3󸀠)
primers. The level of 𝛽-actin was used to normalize loadings
of total RNA [4].
2.7. Effects of Neurotransmitter Antagonists. Test drugs were
used at the following concentrations: anti-KP (10𝜇g/mL);
KP234 (10 𝜇M); RF9 (10 𝜇M); ASCAT (100 𝜇M); BTA-EG4
hydrate (10 𝜇M); naloxone (1 𝜇M); naltrexone (1 𝜇M); atosi-
ban (1𝜇M); phenoxybenzamine hydrochloride (10 𝜇M); pra-
zosin hydrochloride (250 nM); yohimbine hydrochloride
(50 nM); propranolol hydrochloride (50 nM); atropine sul-
phate (10 𝜇M); mecamylamine hydrochloride (10 𝜇M);
haloperidol (10 𝜇M); cyproheptadine hydrochloride (10 nM);
methysergide maleate (1𝜇M); 1(S),9(R)-(−)-bicuculline
methiodide (50𝜇M); tamoxifen (10 𝜇M); 3-Amino-1,2,4-
triazole (50mM); SC-560 (1 𝜇M); NG-Methyl-L-arginine
acetate salt (1mM) and PD98059 (50 𝜇M). Stock solutions
of at least 100x maximum required concentration for testing
were prepared in PBS (anti-KP), ddH
2
O (KP234, RF9,
ASCAT, naloxone, naltrexone, atosiban, yohimbine hydro-
chloride, 1(S),9(R)-(−)-bicuculline methiodide, 3-Amino-
1,2,4-triazole, NG-Methyl-L-arginine acetate salt), methanol
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(phenoxybenzamine hydrochloride, prazosin hydrochlo-
ride), ethanol (atropine sulphate, mecamylamine hydrochlo-
ride, cyproheptadine hydrochloride), or DMSO (BTA-EG4
hydrate, propranolol hydrochloride, haloperidol, methyser-
gide maleate, tamoxifen, SC-560, PD98059) prior to dilution
to the required concentration in cell culture media. On the
day of the experiment 5 × 103 differentiated PKiSS expressing
SH-SY5Y cells/well in 96-well plates were pretreated with
eithermedia alone (control) or test drugs for a 2 h period.The
fibrillar A𝛽 1–40 (10 𝜇M) was then added to induce toxicity
and cells were incubated for a further 16 hours prior to
determination of cell viability. None of the solvents used
(PBS, ddH2O, methanol, ethanol, or DMSO) had a statisti-
cally significant effect on cell viability or A𝛽 1–40 (10 𝜇M)
toxicity at a 1 : 100 dilution in cell culture medium.
2.8. Cell Viability. After treatment with test peptides or drugs
and incubation for the appropriate time the viability was
determined by either trypan blue dye exclusion with at least
100 cells counted per well or by 3-[4,5-dimethylthiazol-2-
yl]- 2,5-diphenyltetrazolium bromide (MTT) reduction [24].
For MTT reduction determination, after incubation with test
substances MTT (10 𝜇L: 12mM stock) was added and cells
incubated for a further 4 hours. Cell lysis buffer [100𝜇L/well;
20% (v/v) SDS, 50% (v/v) N,N-dimethylformamide, pH 4.7]
was added and after repeated pipetting to lyse cells the MTT
formazan product formation was determined by measure-
ment of absorbance change at 570 nm. Control levels in
the absence of test substances were taken as 100% and the
absorbance in the presence of cells lysed with Triton X-100 at
the start of the incubation periodwith test substances taken as
0% [25]. All of the drugs tested had no statistically significant
effect on the MTT assay in the absence or presence of cells.
None of the solvents used (PBS, ddH2O, methanol, ethanol,
or DMSO) had a statistically significant effect on the MTT
assay in the absence or presence of cells.
2.9. Data Analysis. All data are expressed as means± s.e.m.
For cytotoxicity experiments data are expressed as % viable
cells (trypan blue dye exclusion) or % control cells (MTT
reduction). Statistical analysis was performed by one-way
analysis of variance (ANOVA) due to the multiple variables
(A𝛽, test drug, and A𝛽 plus test drug being compared) using
GraphPad Prism software (version 6). Post hoc analysis was
carried with Tukey (for analysis of differences between KiSS-
1 overexpressing and vector cells response to A𝛽) or Dunnett
(for comparisons involving test drugs) multiple comparison
based on the recommendations of GraphPad Prism software
for the data sets concerned, with a𝑃 value of<0.05 considered
statistically significant.
3. Results
3.1. KiSS-1 Overexpression Cell Line Characterization. The
overexpression of the human KiSS-1 gene in the PKiSS SH-
SY5Y neurons, stably transfectedwith the pcDNA4/TO/myc-
His expression vector containing the human KiSS-1 gene, was
confirmed using immunocytochemistry (Figure 1(a)), which
showed that the anti-KP 45–54 staining was found within
the cytoplasm. The staining of PVect control cells, stably
transfected with the pcDNA4/TO/myc-His expression vec-
tor, showed no anti-KP 45–54 staining above the background
levels (Figure 1(b)). Conditioned media from PKiSS SH-
SY5Y neurons and PVect control cells were collected and
the presence of immunoreactive (ir) KP was determined by
western blotting. Results showed the presence of an ir-KP low
molecular weight band (<10 kDa) in media from PKiSS SH-
SY5Y neurons, that was not found in PVect control cells
(Figure 1(c)). To confirm that the transfected KiSS-1 gene was
expressed cells were analyzed by RT-PCR. Results showed a
high level of KiSS-1 mRNA in the PKiSS SH-SY5Y neurons
compared to that found in naive (untransfected) SH-SY5Y
neurons and PVect SH-SY5Y neurons (Figure 1(d)).
3.2. Neuroprotection against Amyloid-𝛽 by KiSS-1 Overex-
pression and the Role of Kisspeptin. The overexpression of
the KiSS-1 gene in SH-SY5Y neurons was shown to be
significantly (𝑃 < 0.0001; one-way ANOVA, Tukey post hoc
test) neuroprotective against A𝛽 25–35 toxicity (Figure 2(a)),
in agreement with the previous studies [1]. Pretreatment with
anti-KP (10 𝜇g/mL), KP234 (10 𝜇M), and RF9 (10 𝜇M) was
tested to confirm the observations from a previous study [1].
The anti-KP antibody significantly (𝑃 = 0.0421; one-way
ANOVA, Dunnett post hoc test) enhanced the toxicity of A𝛽
1–40 (10 𝜇M) in KiSS-1 overexpressing neurons (Figure 2(b)),
whilst neither the KP receptor antagonist KP234 [26] (Fig-
ure 2(c)) nor the NPFF receptor antagonist RF9 [27] (Fig-
ure 2(d)) had any significant effect, in agreement with previ-
ous studies [1].The anti-KP antibody, KP234, and RF9 had no
effect on the KiSS-1 overexpressing neurons alone. The doses
of anti-KP antibody, KP234, and RF9 were selected based
on previous studies [1]. These results suggest that KP is the
neuroprotective component derived from the KiSS-1 gene,
confirming previous studies [1], and indicate that the neuro-
protective actions ofKP are notmediated via actions on either
the KP or NPFF receptors. The results further suggest that
another mechanism, possibly via a different receptor or pro-
tein interactions between KP and A𝛽, may play a role.
3.3. The Role of Amyloid-Binding Interactions in Neuropro-
tection against Amyloid-𝛽 by KiSS-1 Overexpression. The KP
peptides that are suggested to be the neuroprotective deriva-
tives from KiSS-1 overexpression have been shown to specifi-
cally bindA𝛽. A synthetic peptide, ASCAT,which contains an
A𝛽-like sequence [24] and competes with A𝛽 binding to KP
was therefore tested. The dose chosen (100 𝜇M) has previ-
ously been shown to preventA𝛽 inhibition of catalasewithout
having a neuroprotective effect [24] and to prevent KP
binding to amyloid peptides. Results showed that this com-
pound had no significant effect on KiSS-1 overexpression
induced neuroprotection against A𝛽 (Figure 3(a)). The BTA-
EG4 compound, that has been developed as an A𝛽 binding
agent [28], has previously been shown to displace A𝛽 binding
to catalase [29] by binding the CA𝛽BD of A𝛽 [24]. The dose
chosen (10 𝜇M) prevents A𝛽 interactions with catalase but
is not neuroprotective itself [29]. The KP peptide has been
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Figure 1: Characterization of KiSS-1 gene overexpression in SH-SY5Y neurons. (a) Immunocytochemistry of human SH-SY5Y neuron stable
cell line containing the KiSS-1 gene vector (PKiSS) showing localization of kisspeptin in the cytoplasm. (b) Immunocytochemistry of human
SH-SY5Y neuron stable cell line containing the pcDNA4/TO/myc-His expression vector (PVect) showing no localization of kisspeptin above
background. KP appears green (anti-KP 45–54 staining) and the nucleus appears blue (TO-PRO-3 Iodide staining). Bars = 10 𝜇m. (c)Western
blot of conditionedmedia fromPKiSS and PVect cells showing ir-KP staining of a<10 kDa band in PKiSSmedia. (d) RT-PCR analysis of KiSS-
1 and 𝛽-actin mRNA in human SH-SY5Y neurons, human SH-SY5Y neuron stable cell line containing the pcDNA4/TO/myc-His expression
vector (PVect), and human SH-SY5Y neuron stable cell line containing the KiSS-1 gene vector (PKiSS).
shown to bind the CA𝛽BD of A𝛽 [1] and thus BTA-EG4 may
displace KP binding to A𝛽. When BTA-EG4 was tested in
KiSS-1 overexpressing cells the compound had no effect of A𝛽
toxicity (Figure 3(b)). These results suggest that the mecha-
nism for KiSS-1 neuroprotection against A𝛽may not involve
direct protein interactions between KP and A𝛽.
3.4.The Role of Opioid Receptor Activation in Neuroprotection
against Amyloid-𝛽 by KiSS-1 Overexpression. Opioids are
neuroprotective against A𝛽 [30, 31] and also involved in KP
activation of GnRH [12, 13]. The effects of the opioid recep-
tor antagonists naloxone and naltrexone on KiSS-1 overex-
pression neuroprotection against A𝛽 were therefore tested.
The doses of naloxone (1 𝜇M) and naltrexone (1 𝜇M) have
previously been demonstrated to be effective in blocking the
actions of opioids in cell culture models [30, 31]. Results
showed that naloxone significantly (𝑃 = 0.0230; one-way
ANOVA, Dunnett post hoc test) enhanced KiSS-1 overex-
pression neuroprotection against A𝛽 (Figure 4(a)). The nal-
trexone significantly (𝑃 < 0.0001; one-wayANOVA,Dunnett
post hoc test) enhanced MTT reduction in control cells, sug-
gesting that the compound had a proliferative effect on the
KiSS-1 overexpressing neurons (Figure 4(b)). Naltrexone also
significantly (𝑃 = 0.0086; one-way ANOVA, Dunnett post
hoc test) enhanced KiSS-1 overexpression neuroprotection
against A𝛽 (Figure 4(b)).
3.5. The Role of Oxytocin in Neuroprotection against Amyloid-
𝛽 by KiSS-1 Overexpression. TheKP peptide is known to acti-
vate oxytocin in vivo [4]. The SH-SY5Y neurons express oxy-
tocin receptors [32] and oxytocin has neuroprotective actions
in this cell line [33]. The effects of atosiban, an antagonist
of oxytocin [34], on KiSS-1 overexpression neuroprotection
against A𝛽 were therefore tested at a dose (1 𝜇M) that is
known to be effective in cell culture models. Results showed
atosiban significantly (𝑃 = 0.0059; one-way ANOVA, Dun-
nett post hoc test) enhanced the toxicity of A𝛽 in KiSS-1 over-
expressing neurons (Figure 5).This suggests that the oxytocin
receptor systemmay play a role in KiSS-1mediated neuropro-
tection.
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Figure 2: Effect of KiSS-1 gene overexpression on amyloid-𝛽 toxicity. (a) Human SH-SY5Y neurons stable cell lines containing control vector
(PVect) or the KiSS-1 gene vector (PKiSS) were exposed to fibrillar A𝛽 25–35 (10 𝜇M) and cell viability determined by trypan blue exclusion.
PKiSS cells were pretreated with (b) anti-kisspeptin antibody (Anti-KP: 10𝜇g/mL) or (c) kisspeptin receptor antagonist (KP234: 10 𝜇M) or
(d) neuropeptide FF receptor antagonist (RF9: 10 𝜇M) for 2 h prior to exposure to fibrillar A𝛽 1–40 (10 𝜇M) and determination of viability
by MTT reduction. Results are mean± s.e.m. (a) §𝑃 < 0.05 versus PVect; ∗∗𝑃 < 0.05 versus PKiSS; §§𝑃 < 0.05 versus PVect +A𝛽; (b–d)
∗𝑃 < 0.05 versus control (media alone); †𝑃 < 0.05 versus A𝛽 alone; one-way ANOVA.
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Figure 3: Effect of amyloid-binding compounds on KiSS-1 gene overexpression neuroprotection against amyloid-𝛽 toxicity. PKiSS cells were
pretreated with (a) ASCAT peptide (100𝜇M) or (b) BTA-EG4 (10 𝜇M) for 2 h prior to exposure to fibrillar A𝛽 1–40 (10𝜇M) and determination
of viability by MTT reduction. Results are mean± s.e.m. ∗𝑃 < 0.05 versus control (media alone); one-way ANOVA.
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Figure 4: Effect of opioid receptor antagonism on KiSS-1 gene overexpression neuroprotection against amyloid-𝛽 toxicity. PKiSS cells were
pretreated with (a) opioid antagonist naloxone (NAL: 1 𝜇M) or (b) opioid antagonist naltrexone (NALTR: 1𝜇M) for 2 h prior to exposure
to A𝛽 1–40 (10𝜇M) and determination of viability by MTT reduction. Results are mean± s.e.m. ∗𝑃 < 0.05 versus control (media alone);
†𝑃 < 0.05 versus A𝛽 alone; one-way ANOVA.
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Figure 5: Effect of oxytocin receptor antagonism on KiSS-1 gene overexpression neuroprotection against amyloid-𝛽 toxicity. PKiSS cells were
pretreated with atosiban (ATO: 1 𝜇M) for 2 h prior to exposure to A𝛽 1–40 (10𝜇M) and determination of viability by MTT reduction. Results
are mean± s.e.m. ∗𝑃 < 0.05 versus control (media alone); †𝑃 < 0.05 versus A𝛽 alone; one-way ANOVA.
3.6. The Role of Adrenergic Receptor Activation in Neuropro-
tection against Amyloid-𝛽 by KiSS-1 Overexpression. The KP
peptide facilitates passive avoidance learning and memory
consolidation in vivo, which can be inhibited by both 𝛼- and
𝛽-adrenergic antagonists [17]. The KP peptide also has
antidepressant-like activity that can be inhibited by 𝛼2-
adrenergic antagonists [16]. The effects of 𝛼- and 𝛽-adren-
ergic antagonists on KiSS-1 overexpression neuroprotection
against A𝛽 were therefore tested. The doses of phenoxy-
benzamine hydrochloride (10𝜇M), prazosin hydrochloride
(250 nM), yohimbine hydrochloride (50 nM), and propra-
nolol hydrochloride (50 nM) have previously been demon-
strated to be effective in neuronal cell culture models. Results
showed that the 𝛼-adrenergic antagonists phenoxybenza-
mine hydrochloride (Figure 6(a)), prazosin hydrochloride
(Figure 6(b)), and yohimbine hydrochloride (Figure 6(c))
had no significant effect on the toxicity of A𝛽 in KiSS-1 over-
expressing neurons.The𝛽-adrenergic antagonist propranolol
hydrochloride caused a significant (𝑃 < 0.0001; one-way
ANOVA, Dunnett post hoc test) reduction in the viability of
KiSS-1 overexpressing SH-SY5Y neurons (Figure 6(d)), at a
dose that is nontoxic to SH-SY5Y neurons [35]. The propra-
nolol also caused a significant (𝑃 < 0.0001; one-wayANOVA,
Dunnett post hoc test) enhancement of A𝛽 toxicity in the
KiSS-1 overexpressing neurons (Figure 6(d)), suggesting that
the toxicity of propranolol in the KiSS-1 overexpressing cells
was additive to the toxicity of A𝛽.
3.7. The Role of Cholinergic Receptor Activation in Neuropro-
tection against Amyloid-𝛽 by KiSS-1 Overexpression. The KP
peptide facilitates passive avoidance learning and memory
consolidation in vivo, which can be inhibited by muscarinic
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Figure 6: Effect of adrenergic receptor antagonism on KiSS-1 gene overexpression neuroprotection against amyloid-𝛽 toxicity. PKiSS cells
were pretreated with (a) 𝛼-adrenergic antagonist phenoxybenzamine hydrochloride (PHB: 10𝜇M), (b) 𝛼-adrenergic antagonist prazosin
hydrochloride (PR: 250 nM), (c) 𝛼-adrenergic antagonist yohimbine hydrochloride (YO: 50 nM), (d) 𝛽-adrenergic antagonist propranolol
hydrochloride (PROP: 50 nM) for 2 h prior to exposure to A𝛽 1–40 (10 𝜇M) and determination of viability by MTT reduction. Results are
mean± s.e.m. ∗𝑃 < 0.05 versus control (media alone); †𝑃 < 0.05 versus A𝛽 alone; one-way ANOVA.
but not nicotinic cholinergic antagonists [17]. The effects of
muscarinic and nicotinic cholinergic antagonists on KiSS-1
overexpression neuroprotection against A𝛽 were therefore
tested. The doses of atropine sulphate (10𝜇M) and mecamy-
lamine hydrochloride (10 𝜇M) have previously been demon-
strated to be effective in neuronal cell culture models. Results
showed that themuscarinic acetylcholine antagonist atropine
sulphate (Figure 7(a)) and the nicotinic acetylcholine antag-
onist mecamylamine hydrochloride (Figure 7(b)) had no sig-
nificant effect on the toxicity of A𝛽 in KiSS-1 overexpressing
neurons.
3.8. The Role of Dopaminergic Receptor Activation in Neuro-
protection against Amyloid-𝛽 by KiSS-1 Overexpression. The
KP system is known to modulate dopamine levels [36] and
some neurons coexpress KP plus dopamine synthesis
enzymes [37]. The SH-SY5Y neuroblastoma is dopamin-
ergic [38] and the effect of the dopaminergic antagonist
haloperidol was therefore tested on KiSS-1 overexpression
neuroprotection against A𝛽. The dose of haloperidol (10 𝜇M)
has previously been demonstrated to be effective in neuronal
cell culture models. Results showed that haloperidol had no
significant effect on the toxicity of A𝛽 in KiSS-1 overex-
pressing neurons (Figure 8). The dopaminergic antagonist
haloperidol has also been suggested to have neuroprotective
actions against A𝛽 [39], an effect not observed in the KiSS-1
overexpressing neurons.
3.9. The Role of Serotonergic Receptor Activation in Neuropro-
tection against Amyloid-𝛽 by KiSS-1 Overexpression. The KP
peptide facilitates passive avoidance learning and memory
consolidation in vivo, which can be inhibited by 5-HT2 ser-
otonergic antagonists [17]. The KP peptide also has antide-
pressant-like activity that can be inhibited by 5-HT2 sero-
tonergic receptor antagonists [16]. The effects of seroton-
ergic receptor antagonists on KiSS-1 overexpression neu-
roprotection against A𝛽 were therefore tested. The doses
of cyproheptadine hydrochloride (10 nM) and methysergide
8 ISRN Neuroscience
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Figure 7: Effect of cholinergic receptor antagonism on KiSS-1 gene overexpression neuroprotection against amyloid-𝛽 toxicity. PKiSS cells
were pretreated with (a) muscarinic acetylcholine antagonist atropine sulphate (ATR: 10𝜇M) or (b) nicotinic acetylcholine antagonist meca-
mylamine hydrochloride (MEC: 10 𝜇M) for 2 h prior to exposure toA𝛽 1–40 (10𝜇M) and determination of viability byMTT reduction. Results
are mean± s.e.m. ∗𝑃 < 0.05 versus control (media alone); one-way ANOVA.
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Figure 8: Effect of dopaminergic receptor antagonism on KiSS-1 gene overexpression neuroprotection against amyloid-𝛽 toxicity. PKiSS cells
were pretreated with haloperidol (HAL: 10𝜇M) for 2 h prior to exposure to A𝛽 1–40 (10𝜇M) and determination of viability byMTT reduction.
Results are mean± s.e.m. ∗𝑃 < 0.05 versus control (media alone); one-way ANOVA.
maleate (1 𝜇M) have previously been demonstrated to be
effective in neuronal cell culture models. Results showed the
5-HT2 serotonergic antagonist cyproheptadine hydrochlo-
ride (Figure 9(a)) had no significant effect on the toxicity of
A𝛽 in KiSS-1 overexpressing neurons. The mixed 5-HT1/5-
HT2 receptor antagonist methysergide maleate caused a
significant (𝑃 < 0.0001; one-way ANOVA, Dunnett post hoc
test) reduction in the viability of KiSS-1 overexpressing SH-
SY5Y neurons (Figure 9(b)), at a dose that is nontoxic to neu-
ronal cell lines [40]. The methysergide maleate also caused a
significant (𝑃 = 0.0016; one-way ANOVA, Dunnett post hoc
test) enhancement of A𝛽 toxicity in theKiSS-1 overexpressing
neurons (Figure 9(b)), suggesting that the toxicity of methy-
sergide maleate in the KiSS-1 overexpressing cells was addi-
tive to the toxicity of A𝛽.
3.10. The Role of GABA-A Receptor Activation in Neuropro-
tection against Amyloid-𝛽 by KiSS-1 Overexpression. The KP
peptide facilitates passive avoidance learning and memory
consolidation in vivo, which can be inhibited by the GABA-A
antagonist bicuculline [17]. The effect of bicuculline on KiSS-
1 overexpression neuroprotection against A𝛽 was therefore
tested. The dose of 1(S),9(R)-(−)-bicuculline methiodide
(50 𝜇M) has previously been demonstrated to be effective in
neuronal cell culture models. Results showed the bicuculline
had no significant effect on the toxicity of A𝛽 in KiSS-1 over-
expressing neurons (Figure 10).
3.11. The Role of Estrogen Receptor Activation in Neuroprotec-
tion against Amyloid-𝛽 by KiSS-1 Overexpression. Activation
of estrogen receptors is known to alter KP levels [41, 42] and
also plays a role in the neuroprotection against A𝛽 [31, 43].
The effect of the estrogen receptor antagonist tamoxifen on
KiSS-1 overexpression neuroprotection against A𝛽was there-
fore tested. The dose of tamoxifen (10 𝜇M) has previously
been demonstrated to be effective in neuronal cell culture
models. Results showed that tamoxifen had no significant
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Figure 9: Effect of serotonergic receptor antagonism on KiSS-1 gene overexpression neuroprotection against amyloid-𝛽 toxicity. PKiSS cells
were pretreated with (a) serotonergic antagonist cyproheptadine hydrochloride (CYPR: 10 nM) or (b) serotonergic antagonist methysergide
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Figure 10: Effect of GABA receptor antagonism on KiSS-1 gene overexpression neuroprotection against amyloid-𝛽 toxicity. PKiSS cells were
pretreated with the GABA-A antagonist 1(S),9(R)-(−)-bicuculline methiodide (BIC: 50 𝜇M) for 2 h prior to exposure to A𝛽 1–40 (10𝜇M) and
determination of viability by MTT reduction. Results are mean± s.e.m. ∗𝑃 < 0.05 versus control (media alone); one-way ANOVA.
effect on the toxicity of A𝛽 in KiSS-1 overexpressing neurons
(Figure 11).
3.12. The Role of Catalase, Cyclooxygenase, Nitric Oxide
Synthase, and 𝛾-Secretase Enzymes in Neuroprotection against
Amyloid-𝛽 by KiSS-1 Overexpression. The KP peptide is
known to increase catalase activity [18], which is also neu-
roprotective against A𝛽 [44]. The KP peptide also has ther-
moregulatory effects [19] and acts via nitric oxide in the facil-
itation of passive avoidance learning plus memory consolida-
tion in vivo [17]. Another possible mechanism for the neuro-
protective action of KiSS-1 overexpression is via activation of
intracellular second messenger pathways. The effects of
catalase inhibition, cyclooxygenase inhibition, nitric oxide
synthase inhibition, and also the mitogen activated protein
kinase cascade inhibitor PD98059 on KiSS-1 overexpression
neuroprotection against A𝛽 were tested to determine if these
processes were involved.The doses of 3-Amino-1,2,4-triazole
(50mM), SC-560 (1 𝜇M), NG-Methyl-L-arginine acetate salt
(1mM), and PD98059 (50 𝜇M) have previously been demon-
strated to be effective in neuronal cell culture models. Results
showed that catalase inhibition with 3-Amino-1,2,4-triazole
had no effect on KiSS-1 overexpression neuroprotection
against A𝛽 (Figure 12(a)).The cyclooxygenase-1 inhibitor SC-
560 significantly (𝑃 = 0.0029; one-way ANOVA, Dunnett
post hoc test) reducedKiSS-1 overexpressionneuroprotection
against A𝛽 (Figure 12(b)). Nitric oxide synthase inhibition
with NG-Methyl-L-arginine acetate had no effect on KiSS-
1 overexpression neuroprotection against A𝛽 (Figure 12(c)).
The mitogen activated protein kinase cascade inhibitor
PD98059 caused a significant (𝑃 < 0.0001; one-way ANOVA,
Dunnett post hoc test) reduction in the viability of KiSS-1
overexpressing SH-SY5Y neurons (Figure 12(d)), at a dose
that has no effect on SH-SY5Y neurons [45]. The PD98059
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Figure 12: Effect of endogenous enzyme inhibition on KiSS-1 gene overexpression neuroprotection against amyloid-𝛽 toxicity. PKiSS cells
were pretreated with (a) catalase inhibitor 3-Amino-1,2,4-triazole (3AT: 50mM), (b) cyclooxygenase inhibitor SC560 (1 𝜇M), (c) nitric
oxide synthase inhibitor NG-Methyl-L-arginine acetate salt (LNMA: 1mM), (d) mitogen activated protein kinase cascade inhibitor PD98059
(50𝜇M) for 2 h prior to exposure to A𝛽 1–40 (10 𝜇M) and determination of viability by MTT reduction. Results are mean± s.e.m. ∗𝑃 < 0.05
versus control (media alone); †𝑃 < 0.05 versus A𝛽 alone; one-way ANOVA.
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also caused a significant (𝑃 < 0.0001; one-way ANOVA,
Dunnett post hoc test) enhancement of A𝛽 toxicity in the
KiSS-1 overexpressing neurons (Figure 12(d)), suggesting that
the toxicity of PD98059 in the KiSS-1 overexpressing cells was
additive to the toxicity of A𝛽 rather than KiSS-1 neuroprotec-
tion being mediated via activation of the mitogen activated
protein kinase cascade.
4. Discussion
The effects of the anti-KP antibody on KiSS-1 overexpression
neuroprotection against A𝛽 have previously been reported
and the mechanism of neuroprotection by KP has been sug-
gested not to involve either the KP or NPFF receptors [1].The
failure of ASCAT and BTA-EG4 compounds, that modify KP
binding to A𝛽, to modulate this process suggests that the
proposed binding interaction may not mediate the neuro-
protection in this system. The levels of KP released by SH-
SY5Y neurons in response to A𝛽 are likely to be insufficient
to provide full neuroprotection via a binding action [1, 11].
However, in the KiSS-1 overexpressing neurons there is a sig-
nificant release of an ir-KP-like material into the media that
could either bind A𝛽 or activate receptor mediated pathways.
It is therefore likely that the mechanism for neuroprotection
may involve an alternative process that is more likely receptor
mediated. The in vivo actions of KP peptides include actions
on the opioid system [12, 13], oxytocin/vasopressin systems
[4, 14, 15], neurotransmitter systems [16, 17], activation of
endogenous antioxidants [18], activation of nitric oxide [17],
and effects on thermoregulation [19] that could be mediated
via the prostaglandin systems [46, 47].
The naloxone and naltrexone reduction in the toxicity of
A𝛽 raises the possibility that endogenous opioids may play
a role in the toxicity of A𝛽. Similar effects were observed
with naloxone and naltrexone on A𝛽 toxicity; however, these
opioid antagonists had different effects on cell viability itself
which complicated the interpretation of the results. The
antiopioid activity of KP peptides has been suggested by their
activation of NPFF receptors [8, 9] and the KiSS-1 derivative
KSO also acts as an NPFF ligand [10]. However, the NPFF
antagonist RF9 had no effect onKiSS-1 overexpression neuro-
protection against A𝛽.TheRF9 is known to block the antiopi-
oid activity ofNPFF [48] but has recently been suggested to be
ineffective at blocking all the actions of NPFF and related
peptides [49]. As such the effects of KiSS-1 overexpression
on A𝛽 toxicity are unlikely to involve a partial suppression of
endogenous opioid actions by KP that is enhanced by nalox-
one or naltrexone.
The effects of atosiban suggest a role for the oxytocin sys-
tem in the neuroprotection provided by KiSS-1 overexpres-
sion. The actions of atosiban also include inhibition of vaso-
pressin receptors [50] and it is known that some of the actions
of KP peptides are mediated via actions on vasopressin [14].
In vivo KP activates both oxytocin and vasopressin [4, 14, 15],
as such it is possible that either or both the oxytocin and
vasopressin systems are involved in KiSS-1 neuroprotection.
From this study the adrenergic, cholinergic, dopaminer-
gic, serotonergic, and GABA neurotransmitter systems plus
the nitric oxide and estrogen receptor activated systems do
not appear to play a role in the neuroprotective actions of
KiSS-1 overexpression against the A𝛽 peptide. The 𝛽-adren-
ergic antagonist propranolol hydrochloride and the mixed 5-
HT1/5-HT2 receptor antagonist methysergide maleate both
had toxic actions in KiSS-1 overexpressing neurons at con-
centrations that are not toxic to SH-SY5Y neurons [35, 40].
The 𝛽-adrenergic antagonist propranolol hydrochloride and
the mixed 5-HT1/5-HT2 receptor antagonist methysergide
maleate also enhanced A𝛽 toxicity; however, this is more
likely due to the toxicity of these antagonists to KiSS-1
overexpressing neurons rather than the involvement of nora-
drenaline or serotonin in the KiSS-1 mediated neuroprotec-
tion. Both noradrenaline [51, 52] and serotonin [53] have neu-
roprotective properties.Themitogen activated protein kinase
cascade inhibitor PD98059 also inhibited cell viability and the
𝛽-adrenergic [54] plus 5HT1 serotonergic [55] receptors can
act via themitogen activated protein kinase cascade. Since the
KP peptide is known to activate both 𝛽-adrenergic and sero-
tonergic pathways in vivo [17] it is possible that these path-
ways are upregulated in this overexpression system and play
a role in the neuronal survival.Themitogen activated protein
kinase cascade may provide the secondmessenger system for
the 𝛽-adrenergic plus 5HT1 serotonergic pathways involved.
The mitogen activated protein kinase cascade inhibitor
PD98059 has previously been shown to reduce the anti-A𝛽
effects of a number of neuroprotective compounds [56–60].
PD98059 also attenuates KP induced modulation of GnRH
mRNA [61] and KP upregulation of excitatory synaptic trans-
mission [62].
The SC-560 cyclooxygenase-1 inhibitor has previously
been shown to reduce A𝛽 production in an AD model [63].
The specificity of SC-560 for cyclooxygenase-1 over cyclooxy-
genase-2 is altered in some cell systems [64] and it is
unknown which form of cyclooxygenase contributes in the
KiSS-1 overexpression model. The ability of this compound
to enhance A𝛽 toxicity in the KiSS-1 overexpression model
suggests that there may be modulation of the cyclooxygenase
system in these neurons. The ability of KP to modulate ther-
moregulatory responses in vivo [19] could be modulated via
cyclooxygenase inhibitors [46, 47]. As such KP could be act-
ing via prostaglandin synthesis in this overexpression model
and in vivo.
The observation that KiSS-1 neuroprotection has both an
oxytocin/vasopressin plus a cyclooxygenase dependent com-
ponent could be due to endogenous oxytocin or vasopressin
activating cyclooxygenase. Both in vivo adminstration and
in vitro administration of oxytocin [65, 66] or vasopressin
[67, 68] causes an activation of prostaglandin synthesis that is
cyclooxygenase dependent. The SH-SY5Y neuronal cell line
is known to express the vasopressin gene [69] suggesting
that this could be a source of the endogenous material
antagonized by atosiban.This proposedmechanism for KiSS-
1mediated neuroprotection against A𝛽 is summarized in Fig-
ure 13. The action of KP or KSO products of the KiSS-1 gene
appears to be independent of the KP andNPFF receptors and
a direct binding action onA𝛽 cannot be excluded [1] but at the
concentrations of KP found in the system is unlikely to have
a major effect.
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Figure 13: Model for KiSS-1 gene overexpression neuroprotective mechanisms against amyloid-𝛽 toxicity. KP: kisspeptin; KSO: kissorphin;
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receptor antagonist; OTR: oxytocin receptor; VPR: vasopressin receptor; COX-1/2: cyclooxygenase 1 and 2; PG’s: prostaglandins; and SC-560:
cyclooxygenase 1 antagonist.
5. Conclusion
KiSS-1 overexpression is neuroprotective against A𝛽 and the
action appears to involve the KP peptide product of KiSS-1
processing, which is released by the cells. The mechanism of
neuroprotection does not involve the KP or NPFF receptors.
Opioids play a role in the toxicity of A𝛽 in the KiSS-1 over-
expression system. The mechanism of protection appears to
have an oxytocin/vasopressin plus a cyclooxygenase depen-
dent component, which may be linked and can be blocked
by the oxytocin/vasopressin antagonist atosiban or the cyclo-
oxygenase-1 antagonist SC-560 (Figure 13). The contribution
of KP binding to A𝛽may also contribute to the neuroprotec-
tion observed in this model [1].
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